China Resources Boya Bio-pharmaceutical GroupLtd Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Xiaoming Liang
Chief executive officer
CN¥4.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.8yrs |
| CEO ownership | n/a |
| Management average tenure | 3.4yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
CEO
Xiaoming Liang (57 yo)
3.8yrs
Tenure
CN¥4,017,400
Compensation
Mr. Xiaoming Liang serves as Non-Independent Director at Boya Bio-pharmaceutical Group Co., Ltd since February 03, 2021 and also serves as a President. He is a member of the first session of the Biotechnol...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | no data | CN¥4.02m | no data | |
| VP, CFO | 3yrs | CN¥1.69m | no data | |
| Vice President | 3.8yrs | CN¥6.54m | 0.014% CN¥ 2.2m | |
| Vice President | 3.8yrs | CN¥2.48m | no data | |
| Vice President | 2.3yrs | CN¥1.27m | no data |
3.4yrs
Average Tenure
47yo
Average Age
Experienced Management: 300294's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 3.8yrs | CN¥4.02m | no data | |
| VP, CFO | 3yrs | CN¥1.69m | no data | |
| Supervisor | no data | no data | no data | |
| Chairman of Supervisory Board | 3yrs | no data | no data | |
| Non-Employee Representative Supervisor | 7.8yrs | no data | no data | |
| Independent Director | 3.8yrs | CN¥200.00k | no data | |
| Independent Director | 3.8yrs | CN¥200.00k | no data | |
| Independent Director | 3.8yrs | CN¥200.00k | no data | |
| Chairman of the Board | 1.2yrs | no data | no data | |
| Director | 1.2yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
3.0yrs
Average Tenure
54yo
Average Age
Experienced Board: 300294's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:01 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Resources Boya Bio-pharmaceutical Group Co.,Ltd is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Fang Quan | China International Capital Corporation Limited |
| Bing Zhao | China Renaissance Securities |